Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

Rechtien, Anne; Richert, Laura; Lorenzo, Hadrien; Martrus, Glòria; Hejblum, Boris P.; Dahlke, Christine; Kasonta, Rahel; Zinser, Madeleine; Stubbe, Hans; Matschl, Urte; Lohse, Ansgar W.; Krähling, Verena; Eickmann, Markus; Becker, Stephan; Thiébaut, Rodolphe; Altfeld, Marcus; Addo, Marylyn M.

doi:10.1016/j.celrep.2017.08.023

Cited by 109 publications

(119 citation statements)

References 40 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In addition, a systems vaccinology approach identified molecular and cellular immune signatures of a vaccine against Bordetella pertussis [107]. IP-10 was identified as an early innate immune signature that correlated with antibody responses to an Ebola vaccine (rVSV-ZEBOV) [108].…”

Section: New Approaches To Study Adjuvant Modes Of Actionmentioning

confidence: 99%

Selection of adjuvants for vaccines targeting specific pathogens

Sarkar

Garg

Hurk

2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Adjuvants form an integral component in most of the inactivated and subunit vaccine formulations. Careful and proper selection of adjuvants helps in promoting appropriate immune responses against target pathogens at both innate and adaptive levels such that protective immunity can be elicited. Areas covered: Herein, we describe the recent progress in our understanding of the mode of action of adjuvants that are licensed for use in human vaccines or in clinical or pre-clinical stages at both innate and adaptive levels. Different pathogens have distinct characteristics, which require the host to mount an appropriate immune response against them. Adjuvants can be selected to elicit a tailor-made immune response to specific pathogens based on their unique properties. Identification of biomarkers of adjuvanticity for several candidate vaccines using omics-based technologies can unravel the mechanism of action of modern and experimental adjuvants. Expert opinion: Adjuvant technology has been revolutionized over the last two decades. In-depth understanding of the role of adjuvants in activating the innate immune system, combined with systems vaccinology approaches, have led to the development of next-generation, novel adjuvants that can be used in vaccines against challenging pathogens and in specific target populations. ARTICLE HISTORY

show abstract

Section: New Approaches To Study Adjuvant Modes Of Actionmentioning

confidence: 99%

Selection of adjuvants for vaccines targeting specific pathogens

Sarkar

Garg

Hurk

2019

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…We investigated innate immune responses following VSV-EBOV immunization and our data revealed an innate immune signature that correlated with antibody responses in the Hamburg VSV-EBOV vaccine trial. 71 In addition, changes in expression levels of circulating miRNAs have been associated with increased EBOV GP-specific antibody titers. Furthermore, innate immune signatures were assessed in vaccinees from Europe and Africa, revealing an early induction at day 1 p.v.…”

Section: Correlates Of Protection and Duration Of Immune Responsesmentioning

confidence: 99%

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Fathi

Dahlke

Addo

2019

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens. ARTICLE HISTORY

show abstract

“…Development of antigen-specific T cells and their cytokine profiles, as well as the induction of innate immune responses, will need to be directly analysed to understand earlier immune responses. 26,27 Additionally, the correlates of immunity that reflect long-term clinical protection, and whether they are similar or different from those mediating immediate protection, need to be understood. 28 Data from non-human primate models and clinical phase 1 studies of combined Ad26.ZEBOV and MVA-BN-Filo vaccination 15 provide evidence of an important role for cellular immunity, particularly CD8-positive T cells producing tumour necrosis factor α and interferon γ (with or without interleukin 2).…”

mentioning

confidence: 99%